Literature DB >> 19911440

The health value and cost of care for major depression.

Katherine E Watkins1, M Audrey Burnam, Maria Orlando, José J Escarce, Haiden A Huskamp, Howard H Goldman.   

Abstract

BACKGROUND: Trade-offs between costs and outcomes are a reality of health-care decisions. Cost-effectiveness analyses can guide choices toward interventions with the most health benefit for the least cost but are limited because generic measures of health value are infrequently available in the literature and are expensive to collect.
OBJECTIVE: We report on the application of a new approach to estimate the health value of alternative treatment patterns. We apply this approach to common treatment patterns for major depression, and we generate estimates of the change in health value that is attributable to a particular treatment. We also obtain estimates of treatment costs and report cost/health value ratios. We used a modified expert panel approach to estimate the change in health value attributable to different patterns of treatment. We used claims and pharmacy data to define usual care treatment patterns and estimate costs.
RESULTS: The lowest cost and most frequent treatment, 1 to 3 psychotherapy visits, produces minimal improvement. Treatments that include an antidepressant medication provide more health benefit per unit cost than all other treatments and adding a medication follow-up visit provides a lot of benefit for minimal cost.
CONCLUSIONS: We demonstrate the application of a new approach to estimate the health value of common depression treatment practices in the United States. Our results suggest cost-effective targets for quality improvement efforts by identifying ways in which treatment for depression could cost less to get to a given outcome. Because our approach uses a generic health outcome measure, it can be applied to other conditions, permitting comparisons of benefit across diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19911440     DOI: 10.1111/j.1524-4733.2008.00388.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  5 in total

1.  A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment.

Authors:  Scarlett Carmen Johnson; Daniel Clay Williams; Daniel Brinton; Marshall Chew; Annie Simpson; Annie Lintzenich Andrews
Journal:  Hosp Pediatr       Date:  2020-12-08

2.  Blended vs. face-to-face cognitive behavioural treatment for major depression in specialized mental health care: study protocol of a randomized controlled cost-effectiveness trial.

Authors:  Lisa C Kooistra; Jenneke E Wiersma; Jeroen Ruwaard; Patricia van Oppen; Filip Smit; Joran Lokkerbol; Pim Cuijpers; Heleen Riper
Journal:  BMC Psychiatry       Date:  2014-10-18       Impact factor: 3.630

3.  Assessing value in health care: using an interpretive classification system to understand existing practices based on a systematic review.

Authors:  Brayan V Seixas; François Dionne; Tania Conte; Craig Mitton
Journal:  BMC Health Serv Res       Date:  2019-08-13       Impact factor: 2.655

4.  Effectiveness and cost effectiveness of guided online treatment for patients with major depressive disorder on a waiting list for psychotherapy: study protocol of a randomized controlled trial.

Authors:  Robin Maria Francisca Kenter; Annemieke van Straten; Sabine Heleen Hobbel; Filip Smit; Judith Bosmans; Aartjan Beekman; Pim Cuijpers
Journal:  Trials       Date:  2013-12-01       Impact factor: 2.279

5.  Does online insomnia treatment reduce depressive symptoms? A randomized controlled trial in individuals with both insomnia and depressive symptoms.

Authors:  T van der Zweerde; A van Straten; M Effting; S D Kyle; J Lancee
Journal:  Psychol Med       Date:  2018-05-11       Impact factor: 7.723

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.